Argos Therapeutics (NASDAQ: ARGS) shares jumped more than 17% this morning on the company’s report of immunogenicity data from a study of AGS-004 dendritic cell therapy in patients treated during acute HIV infection. AGS-004 is an autologous cell therapy manufactured using the Arcelis® precision immunotherapy technology platform. During the open label study conducted at the University of North Carolina and Duke University, AGS-004 was produced on an individual basis for each patient. The study achieved its primary endpoint, with all six patients demonstrating a positive immune response. These data were recently published in the Journal of AIDS Research and Human Retroviruses. “This is an important first step in our goal of not only combating active HIV infection, but also of eliminating the HIV viral reservoir, which has not yet been achieved with any currently available agent or combination therapy. We are hopeful that our strategy of stimulating cells that are latently infected with the HIV virus with the latency-reversing agent vorinostat will enable AGS-004-stimulated memory / effector T-cells to identify and eliminate these latently infected cells, thus potentially eliminating the HIV viral reservoir,” Argos Chief Scientific Officer Charles Nicolette, PhD, stated in the news release.
To view the full press release, visit: http://nnw.fm/Oe8u6
About Argos Therapeutics
Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos’ most advanced product candidate, Rocapuldencel-T, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). In addition, Rocapuldencel-T is being studied in a phase 2 investigator-initiated clinical trial as neoadjuvant therapy for renal cell carcinoma (RCC). Argos is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in combination with vorinostat, a latency-reversing drug, in an investigator-initiated phase 2 clinical trial aimed at HIV eradication in adult patients. Funding for the development of AGS-004 has been provided by the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and the Collaboratory of Research for AIDS Eradication. To learn more, visit www.argostherapeutics.com.
More from NetworkNewsBreaks
Net Element’s (NASDAQ: NETE) PayOnline Announces Support for iDEAL
Neuralstem, Inc. (NASDAQ: CUR) Shares Plunge on Top-line Phase 2 Data of NSI-189 for MDD
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
